Caricamento...
Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?
Although imatinib is a standard treatment for metastatic or recurrent gastrointestinal stromal tumors (GISTs), acquired c-kit mutations reportedly cause secondary resistance to imatinib. Sunitinib is a tyrosine kinase inhibitor (TKI) that can be used as second-line therapy in imatinib-resistant or -...
Salvato in:
| Pubblicato in: | Transl Gastroenterol Hepatol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
AME Publishing Company
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5897690/ https://ncbi.nlm.nih.gov/pubmed/29682621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tgh.2018.02.02 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|